Emergent Biosolutions Inc. (EBS)
Россия
  • Россия
  • Украина

Emergent Biosolutions Inc. (EBS)

Contact Details

400 Professional Dr # 400, Gaithersburg, Maryland, USA 20879-3457
(240) 631-3200
400 Professional Dr # 400, Gaithersburg, Maryland, USA 20879-3457

General Information

EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission - to protect life. EBS develops, manufactures and commercializes vaccines and therapeutics that assist the body`s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product, BioThrax? (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection.

Contact Information

Phone(240) 631-3200
Fax(301) 795-1899
Website 1http://www.ebsi.com
Website 2http://www.biosolutions.com
Twitter@emergentbiosolu
Thomson Reuters PermID8589934296

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
President and CEO$4,147,386201491.9%
Divisional Executive VP$1,241,984201454.2%
Chairman of the Board$3,591,3732014177.2%
Divisional Executive VP, CFO and Treasurer$1,917,9872014139.5%
Divisional Executive VP$1,298,655201467.5%

Government Contracts

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

SIC Industries

  • Pharmaceutical Preparations
  • Bacterial Vaccines

Company Size

Sales Volume$523 million
Employees1,292

Ownership

Ticker SymbolEBS
ExchangeNew York Stock Exchange (NYSE)
Year Founded1998

Stocks

Previous Close38.95
Open39.18
Bid37.60 x 200
Ask44.00 x 100
Day`s Range38.25 - 39.39
52-Week Range28.25 - 40.28
Average Volume (1M)403,305
Forward P/E19.87x
Trailing P/E26.5x
Beta1.21x
Market Cap.$1,551.46 Million
Last Dividend Amount0
1y Target Price Est.38

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue168,104164,940126,11263,633
Cost of Revenue39,77038,51127,26618,748
Gross Profit128,334126,42998,84644,885
Research Development32,48641,86840,94138,702
Selling General and Administrative45,95631,55636,45334,493
Depreciation and Amortization----
Other Operating Expenses----
Total Operating Expenses118,212111,935104,66091,943
Other Income/Expenses Net----
Earnings Before Interest and Taxes49,89253,00521,452(28,310)
Interest Expense1,5991,6351,6281,661
Income Before Tax47,88252,07619,600(29,789)
Income Tax Expense14,53415,1345,500(8,269)
Minority Interest----
Net Income from Continuing Ops33,34836,94214,100(21,520)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income33,34836,94214,100(21,520)
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares33,34836,94214,100(21,520)